{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=7",
    "query": {
      "intervention": "Torisel",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 647,
    "total_pages": 65,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T14:56:24.742Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00335764",
      "title": "Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2006-04",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00335764"
    },
    {
      "nct_id": "NCT02019693",
      "title": "A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "INC280",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-01-24",
      "completion_date": "2021-12-17",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019693"
    },
    {
      "nct_id": "NCT04177004",
      "title": "Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplant Recipient",
        "Hematopoietic and Lymphoid Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fractionated Stereotactic Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Goat Milk",
          "type": "DRUG"
        },
        {
          "name": "Palifermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2021-04-30",
      "completion_date": "2026-10-27",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177004"
    },
    {
      "nct_id": "NCT01517243",
      "title": "Phase II Study of Alternating Sunitinib and Temsirolimus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2010-09-22",
      "completion_date": "2018-08-20",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 2,
      "location_summary": "Lebanon, New Hampshire • Burlington, Vermont",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01517243"
    },
    {
      "nct_id": "NCT04199026",
      "title": "Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Sarcoma",
        "Recurrent Sarcoma",
        "Resectable Sarcoma"
      ],
      "interventions": [
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Drug Delivery Microdevice",
          "type": "DEVICE"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Ganitumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Polyethylene Glycol",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-25",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199026"
    },
    {
      "nct_id": "NCT03952637",
      "title": "A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lysosomal Diseases",
        "Gangliosidosis",
        "GM1"
      ],
      "interventions": [
        {
          "name": "AAV9-GLB1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abdominal ultrasound",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Audiology assessment with ABR",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Bone density scan (DEXA)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Electrocardiogram (EKG)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Electroencephalogram (EEG) awake and extended overnight",
          "type": "OTHER"
        },
        {
          "name": "Laboratory tests",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Lumbar puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Brain MRI/MRS/fMRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Neurocognitive testing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Neurology exam",
          "type": "OTHER"
        },
        {
          "name": "PICC or other Central line placement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Skeletal survey",
          "type": "PROCEDURE"
        },
        {
          "name": "Skin biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Speech and modified barium swallow study",
          "type": "PROCEDURE"
        },
        {
          "name": "Ophthalmology exam",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "DIAGNOSTIC_TEST",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Months to 12 Years"
      },
      "enrollment_count": 54,
      "start_date": "2019-08-19",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03952637"
    },
    {
      "nct_id": "NCT01049841",
      "title": "Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Solid Tumors"
      ],
      "interventions": [
        {
          "name": "perifosine + temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 23,
      "start_date": "2010-01",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049841"
    },
    {
      "nct_id": "NCT00635284",
      "title": "ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ABI-009",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2007-12-01",
      "completion_date": "2011-06-01",
      "has_results": false,
      "last_update_posted_date": "2019-10-18",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 2,
      "location_summary": "Santa Monica, California • Houston, Texas",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00635284"
    },
    {
      "nct_id": "NCT02833506",
      "title": "Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IIA Fallopian Tube Cancer",
        "Stage IIA Ovarian Cancer",
        "Stage IIB Fallopian Tube Cancer",
        "Stage IIB Ovarian Cancer",
        "Stage IIC Fallopian Tube Cancer",
        "Stage IIC Ovarian Cancer",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Recombinant NY-ESO-1 Protein",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2017-12-08",
      "completion_date": "2019-08-15",
      "has_results": false,
      "last_update_posted_date": "2018-05-01",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833506"
    },
    {
      "nct_id": "NCT02484664",
      "title": "COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphangioleiomyomatosis (LAM)"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2016-06-15",
      "completion_date": "2018-11-19",
      "has_results": true,
      "last_update_posted_date": "2022-01-20",
      "last_synced_at": "2026-10-27T14:56:24.742Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02484664"
    }
  ]
}